Sponsored by AbbVie Medical Affairs
Peter Nash drpnash
3 months 2 weeks ago
3 pain clusters in AxSpA - tres intéressant @RheumNow #EULAR2024 https://t.co/ZgXvsxHlJu
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0202 looks at phenotypes of #RAILD in a cluster analysis
🌎Large multinational cohort
2⃣Two key clusters identified
📈Male sex, older age at RA & ILD onset, European ethnicity, smoking and CCP & RF positivity more frequent in cluster 1 vs 2
@RheumNow #EULAR2024 @Juge_P_A
Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk. While not recommended, 42.5% of women initiating Dmab discontinued treatment for at least one year, which almost doubled their fracture risk. No increased risk was observed for long term discontinuation of IV BP.
Dr. John Cush RheumNow
3 months 2 weeks ago
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty
Aurelie Najm AurelieRheumo
3 months 2 weeks ago
GOLMePsA RCT early naive PsA
Golimumab or PBO in addition to MTX+IM GCs
No difference wk52
ACR20 GOL 76% PBO 55%
MDA GOL 55% PBO 41%
PBO arm received higher GC dose
No new safety signal
@RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm
Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
📺 Join @RheumNow, @Yuz6Yusof & I for the Daily Recap over on @YouTube
⏩ https://t.co/D3HZGUdi9t
⏰ TODAY 18:00 CEST
👋 See you there!
#EULAR2024
Bella Mehta bella_mehta
3 months 2 weeks ago
Nationwide epi study of lymphoproliferative disorders in Sjogren's. All pts in France!
4 % prevalence
More in males and those with cryos and MGUS
#EULAR2024
@rheumnow
abst#OP0207 https://t.co/bEaWpTD7x3
Bella Mehta bella_mehta
3 months 2 weeks ago
Severe refractory Sjogrens - not in RCTs but some meds such as CD20 - Obinutuzumab, CART have been reported.
A summary of slides @RheumNow https://t.co/9HQRAj3rzt
Bella Mehta bella_mehta
3 months 2 weeks ago
CD40 and CD40L (CD154) inhibition
CD-40 monoclonal antibody
CD 40 Ligand blockade- Dazodalibep
@RheumNow https://t.co/n9CcrujVwa
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 2 weeks ago
#EULAR2024 POS0237 RNA-seq of muscle biopsy in inflammatory myopathy (IIM) showed distinct gene expressions underlying muscle damage between DM, Antisynthetase & PM. Potential targets for future therapeutics @RheumNow @IzukaShinji https://t.co/nf0pp2RhaE
Bella Mehta bella_mehta
3 months 2 weeks ago
Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024
Many failed trails - likely secondary to non validated outcomes.
3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2
Bella Mehta bella_mehta
3 months 2 weeks ago
"T and B cells playing tennis" In Sjogren's Syndrome!
Thomas Dorner - #EULAR2024 @rheumnow https://t.co/Lum0A9cY9U